Genprex is a clinical stage gene therapy company focusing on the development of gene-based therapies. Co.'s oncology platform utilizes its non-viral ONCOPREX Nanoparticle Delivery System. Co.'s primary oncology drug candidate, REQORSA Immunogene Therapy, is being developed in combination with cancer drugs to treat Non-Small Cell Lung Cancer and Small Cell Lung Cancer. The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. In diabetes, Co. has licensed from the University of Pittsburgh of the Commonwealth System of Higher Education multiple technologies relating to the development of a gene therapy product for each of Type 1 and Type 2 diabetes. The GNPX average annual return since 2018 is shown above.
The Average Annual Return on the GNPX average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GNPX average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GNPX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|